- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dynavax Technologies Corporation (DVAX)
Assess today's live Dynavax Technologies Corporation (DVAX) share price, performance and insights using our live NASDAQ: DVAX stock exchange data.
Analyse the historical data and Dynavax Technologies Corporation share price performance charts on this page. Our technical summary section provides analysis on Dynavax share price buy/sell indicators using real-time data (or discuss the Dynavax (DVAX) stock price today with other investors in the Dynavax NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ DVAX share price (ISIN: US2681582019) to enhance your trading decisions with our free investment tools and resources.
What Is the Dynavax Technologies Corporation Share Price Today?
The Dynavax share price today is 15.615.
What Is the Stock Symbol for Dynavax Technologies Corporation
The stock symbol (or 'ticker') for Dynavax Technologies Corporation is "DVAX."
What Stock Exchange Does Dynavax Technologies Corporation Trade On?
Dynavax Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is Dynavax Technologies Corporation a Good Stock to Buy?
Determining whether Dynavax Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Dynavax Technologies Corporation share price performance charts on this page. Our technical summary section provides analysis on Dynavax share price buy/sell indicators using real-time data (or discuss the Dynavax (DVAX) stock price today with other investors in the Dynavax NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ DVAX share price (ISIN: US2681582019) to enhance your trading decisions with our free investment tools and resources.
What Is the Dynavax Technologies Corporation Share Price Today?
The Dynavax share price today is 15.615.
What Is the Stock Symbol for Dynavax Technologies Corporation
The stock symbol (or 'ticker') for Dynavax Technologies Corporation is "DVAX."
What Stock Exchange Does Dynavax Technologies Corporation Trade On?
Dynavax Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is Dynavax Technologies Corporation a Good Stock to Buy?
Determining whether Dynavax Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
15.615
-0.015(-0.10%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.610
15.650
52 wk Range
9.200
15.730
DVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.61015.650
52 wk Range
9.20015.730
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
22.000
Upside
+40.89%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Dynavax Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Dynavax Technologies Corporation SWOT Analysis
HEPLISAV-B Dominance | Explore Dynavax's market leadership with HEPLISAV-B, capturing 45% of the U.S. hepatitis B vaccine market and driving robust financial performance |
Pipeline Potential | Delve into Dynavax's diverse vaccine pipeline, including candidates for shingles, plague, and Lyme disease, positioning the company for future growth |
Financial Strength | Learn about Dynavax's strong cash position of $625 million, supporting R&D efforts and strategic initiatives while maintaining financial stability |
Market Outlook | Analysts project a $32 price target, with the U.S. adult hepatitis B vaccine market expected to reach $900 million by 2030, promising continued growth |
Dynavax Technologies Corporation Earnings Call Summary for Q3/2025
- Dynavax reported Q3 2025 EPS of $0.21, exceeding forecasts by 61.54%, with revenue reaching $94.9 million, up 18% year-over-year, driving a 2.49% stock increase in aftermarket trading.
- Flagship product Heplisav-B captured 46% market share, with significant retail sector gains, contributing to net product revenue of $90 million, a 13% increase from Q3 2024.
- GAAP net income rose to $27 million from $18 million in Q3 2024, while non-GAAP adjusted EBITDA reached $36 million, up from $25 million last year.
- Management raised full-year 2025 adjusted EBITDA guidance to at least $80 million and projected Heplisav-B revenue between $315-325 million by year-end.
- CEO Ryan Spencer highlighted upcoming pipeline milestones in H2 2026, including potential expansions in COVID-19 and shingles vaccine programs with opportunities for strategic partnerships.
Last Updated: 05/11/2025, 22:24
Read Full TranscriptCompare DVAX to Peers and Sector
Metrics to compare | DVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −40.9x | 13.3x | −0.6x | |
PEG Ratio | 0.12 | 0.10 | 0.00 | |
Price/Book | 3.3x | 4.0x | 2.6x | |
Price / LTM Sales | 5.4x | 7.3x | 3.4x | |
Upside (Analyst Target) | 59.9% | 39.8% | 41.5% | |
Fair Value Upside | Unlock | 11.8% | 5.5% | Unlock |
Analyst Ratings
1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 22.000
(+40.89% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
0.21 / 0.13
Revenue / Forecast
94.90M / 94.41M
People Also Watch
FAQ
What Is the Dynavax (DVAX) Share Price Today?
The live Dynavax share price today is 15.615
What Stock Exchange Does Dynavax (DVAX) Trade On?
Dynavax is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Dynavax?
The stock symbol (also called a 'ticker') for Dynavax is "DVAX."
What Is the Current Dynavax Market Cap?
As of today, Dynavax market capitalisation is 1.78B.
What Is Dynavax's (DVAX) Earnings Per Share (TTM)?
The Dynavax EPS is currently -0.36 (Trailing Twelve Months).
When Is the Next Dynavax Earnings Date?
Dynavax's next earnings report will be released on 19 Feb 2026.
Is DVAX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Dynavax moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Dynavax Stock Split?
Dynavax has split 1 times. (See the DVAX stock split history page for full effective split date and price information.)
How Many Employees Does Dynavax Have?
Dynavax has 405 employees.
What is the current trading status of Dynavax (DVAX)?
As of 20 Jan 2026, Dynavax (DVAX) is trading at a price of 15.615, with a previous close of 15.630. The stock has fluctuated within a day range of 15.610 to 15.650, while its 52-week range spans from 9.200 to 15.730.
What Is Dynavax (DVAX) Price Target According to Analysts?
The average 12-month price target for Dynavax is USD22.000, with a high estimate of USD25 and a low estimate of USD16. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +40.89% Upside potential.
What Is the DVAX Premarket Price?
DVAX's last pre-market stock price is 15.620. The pre-market share volume is 4,860.000, and the stock has decreased by -0.010, or -0.060%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.